Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Alpha Cognition Inc ACOG

Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062... see more

NDAQ:ACOG - Post Discussion

Alpha Cognition Inc > $ACOG A-1062 helps with TBI and Alzheimer's
View:
Post by StockHawk1 on Dec 17, 2021 6:00pm

$ACOG A-1062 helps with TBI and Alzheimer's

12% of people from 80-85 are diagnosed with dementia (including Alzheimer's).Source: https://www.canada.ca/en/public-health/services/publications/diseases-conditions/dementia-highlights-canadian-chronic-disease-surveillance.html
 
There already is a huge demand for Alzheimer's treatment and that demand will only be growing as the population ages.
 
Alpha Cognition ( $ACOG.V  $ACOGF ) is a biopharmaceutical company that is developing medication for Alzheimer's, ALS, and other neurodegenerative disorders. 
 
$ACOG's ALPHA-1062 drug, which has been shown to help with the effects of Alzheimer's, was also found to help with traumatic brain injury.
 
The drug reduced the extent of functional deficits and improved functional recovery of animals with TBIs.
 
This study displays the diversity of what ALPHA-1062 can be used for. (read more on this study here: https://finance.yahoo.com/news/alpha-cognition-announce-data-pre-140000753.html)
 
Their ALS focused medication is also looking very promising and I would highly suggest reading about it here: https://www.alphacognition.com/our-approach/alpha-0602/)
 
Right now $ACOG is trading at just $1.17, MC $71.951M
 
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities